Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Dexivacaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mepivacaine SCHEMBL1131771 | 1.00 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL30335090 | 1.00 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL34245 | 1.00 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL34246 | 0.99 | KCNK3 (0.72) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL25314 | 0.99 | KCNK3 (0.72) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Dexivacaine SCHEMBL25315 | 0.99 | KCNK3 (0.72) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL2565234 | 0.97 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL5685622 | 0.97 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL2553896 | 0.96 | KCNK3 (0.69) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| SCHEMBL18485518 | 0.94 | CYP3A4 (0.74) | KCNK3LMNACYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021185-A1 | LOCAL ANESTHETIC SOLUTION FOR DENTAL AND/OR CONTRAST MEDIA USE | NEOCAINE LLC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4426316-A1 | RHEOLOGICALLY SYNOVIAL FLUID-LIKE HYDROGEL FORMULATIONS FOR USING IN INTRA-ARTICULAR APPLICATIONS | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi (TR) | 2024-09-11 | — | — | EP | claimed |
| CN-118416028-A | Oral mucosa repair film and preparation method and application thereof | 宁波市第二医院 | 2024-08-02 | — | — | CN | claimed |
| US-11786515-B2 | Anesthetic mixtures formulations for local anesthesia, at very low concentration, to be used cold with suitable packaging | CAPPELLETTI, Renato (IT) | 2023-10-17 | — | — | US | claimed |
| CN-116236445-A | Mepivacaine hydrochloride liposome and preparation method thereof | 广州曼翔医药有限公司 | 2023-06-09 | — | — | CN | claimed |
| WO-2023080853-A1 | RHEOLOGICALLY SYNOVIAL FLUID-LIKE HYDROGEL FORMULATIONS FOR USING IN INTRA-ARTICULAR APPLICATIONS | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2023-05-11 | — | — | WO | claimed |
| CN-114591221-A | Preparation method of high-purity mepivacaine hydrochloride | 广州曼翔医药有限公司 | 2022-06-07 | — | — | CN | claimed |
| EP-3574901-B1 | INJECTION DEVICES COMPRISING A COMPOSITION OF HYALURONIC ACID AND MEPIVACAINE HYDROCHLORIDE | TEOXANE (CH) | 2022-01-26 | — | — | EP | claimed |
| CN-113648459-A | Composition comprising hyaluronic acid and mepivacaine | 泰奥赛恩公司 | 2021-11-16 | — | — | CN | claimed |
| US-20210338819-A1 | METHOD OF ADMINISTERING LOCAL ANESTHETIC SOLUTION FOR DENTAL AND/OR CONTRAST MEDIA USE | NEOCAINE, LLC | 2021-11-04 | — | — | US | claimed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | claimed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
| CN-1091317-A | Improve the part input of medicine | PROCTER & GAMBLE (US) | 1994-08-31 | — | — | CN | claimed |
| US-5322689-A | Topical aromatic releasing compositions | THE PROCTER & GAMBLE COMPANY (US) | 1994-06-21 | — | — | US | claimed |
| CN-1079896-A | The compositions of topical aromatic releasing | RICHARDSON VICKS INC (US) | 1993-12-29 | — | — | CN | claimed |
| WO-1993017655-A1 | TOPICAL AROMATIC RELEASING COMPOSITIONS | RICHARDSON VICKS INC. (US) | 1993-09-16 | — | — | WO | claimed |
| CN-1072863-A | Be used to improve the dermal osmosis system of the reinforcement of medicine localized delivery | RICHARDSON VICKS INC (US) | 1993-06-09 | — | — | CN | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| US-4213876-A | Multi-purpose blood diluent for use in electronic blood analysis instrumentation | COULTER ELECTRONICS, INC. (US) | 1980-07-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021185-A1 | LOCAL ANESTHETIC SOLUTION FOR DENTAL AND/OR CONTRAST MEDIA USE | TAS2R10, TAS2R5, SLC6A1 | KCNK3 1000/4885LMNA 2835/4885CYP3A4 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.